Companies specialising in artificial intelligence (AI) in healthcare are in “rude health” and are set for exponential growth over the next five years, according to a new report.
Drug discovery firm Exscientia has claimed a world first after announcing that the first precision engineered drug generated by artificial intelligence (AI) is entering clinical trials.
As access to healthcare professionals (HCPs) declines, the challenges facing sales representatives continue to increase: less time with HCPs, Sunshine Act restrictions, and integration of p